Correction to: Cell Death & Disease https://doi.org/10.1038/s41419-025-07711-z, published online 25 May 2025
After publication, we noted an unintentional error in the final assembly of Figure 4e (left panel). The representative image for the gRen sample treated with osimertinib (0.5 µM) was inadvertently duplicated from the gRen untreated control condition (Control). This correction pertains only to the representative image and does not alter the quantitative analysis in Figure 4e (right panel) or affect the interpretations or conclusions of the study. We apologize for this oversight.
Original Figure 4
Amended Figure 4
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dayanc, B., Eris, S., Gulfirat, N.E. et al. Correction: Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer. Cell Death Dis 17, 399 (2026). https://doi.org/10.1038/s41419-026-08740-y
Published:
Version of record:
DOI: https://doi.org/10.1038/s41419-026-08740-y
